CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and ...

("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

NeurAxis, Inc. announced that Molina Healthcare will cover its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, which is FDA-cleared for treating functional abdominal ...

MindHYVE.ai is a leader in domain-specific AI models and AGI agents, redefining operational excellence with smarter ...

Impairment in language is a common finding among individuals with dementia and can be a presenting symptom, particularly in Alzheimer's dementia and primary progressive aphasia. Early recognition ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.